December 7, 2017 02:28 PM EST
Peer Review

Daniel Swish­er leaves an ail­ing Sune­sis and swoops in to lead Jazz Phar­ma­ceu­ti­cals

Brittany Meiling

Daniel Swish­er, the CEO of the strug­gling Sune­sis Phar­ma­ceu­ti­cals, has been re­cruit­ed to glob­al bio­phar­ma Jazz Phar­ma­ceu­ti­cals as the com­pa­ny’s new pres­i­dent and chief op­er­a­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times